A Novel Antibody-Drug Conjugate Targeting CCR7 in Hematologic Malignancies

被引：2

作者：

Dang, Anhthu ^{[1
]}

Knee, Deborah ^{[2
]}

Wang, Cui Ying ^{[2
]}

Gao, Feng ^{[2
]}

Liu, Guoxun ^{[2
]}

Briones, Sergio ^{[2
]}

Coulson, Michelle ^{[3
]}

Makofske, Jessica ^{[1
]}

Mansfield, Keith ^{[1
]}

Liu, May ^{[1
]}

Mulvey, Tanya ^{[1
]}

Meseck, Emily K. ^{[4
]}

Woolfenden, Steve ^{[1
]}

Buchanan, Sean G. ^{[2
]}

Steensma, David ^{[1
]}

Askoxylakis, Vasileios ^{[1
]}

机构：

[1] Novartis Inst BioMed Res, Cambridge, MA USA

[2] Novartis Inst BioMed Res, San Diego, CA USA

[3] Novartis Pharmaceut, Preclin Safety, Cambridge, MA USA

[4] Novartis Pharmaceut, Preclin Safety, E Hanover, NJ USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-159910

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：11564 / 11565

页数：2

共 50 条

[41] Immunotherapeutic Targeting of Mesothelin in Acute Myeloid Leukemia in Vitro with Anetumab Ravtansine and a Novel Antibody-Drug Conjugate
Kaeding, Allison
Tarlock, Katherine
Kolb, E. Anders
Meshinchi, Soheil
BLOOD, 2018, 132
[42] In vitro characterization of a novel TROP2-targeting antibody-drug conjugate OBI992
Kuo, Tzer-Min
Chang, Ting-Yu
Huang, Jye-Yu
Tang, Wei-Chien
Lin, Chun-Jung
Wu, Yi-Chen
Lu, Chi-Huan
Weng, Hao-Cheng
Chen, Yu-Jung
Tsao, Yu-Hsuan
Wei, Cheng-Yen
Shen, Lifen
Li, Wan-Fen
Lai, Ming-Tain
CANCER RESEARCH, 2024, 84 (06)
[43] Development of a novel antibody-drug conjugate targeting both CEACAM5 and CEACAM6
Arias, K.
Enos, C.
Spear, M.
Austin, D.
Almofeez, R.
Kortchak, S.
Pincus, L.
Kwon, Y.
Gelber, C.
EUROPEAN JOURNAL OF CANCER, 2022, 174 : S87 - S87
[44] Development of novel MUC1-C targeting antibody-drug conjugate for pancreatic cancer treatment
Ahmad, Rehan
Panchamoorthy, Govind
Raina, Deepak
Lawney, Brian
Kharbanda, Surender
Jasuja, Ravi
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[45] BCG022: A novel bispecific antibody-drug conjugate targeting HER3 and MET
Li, Zhuolin
Shang, Chengzhang
Guan, Xuewa
Han, Zhenyan
An, Gao
Zhang, Ellen
Lin, Qingcong
Yang, Yi
CANCER RESEARCH, 2023, 83 (08)
[46] Preclinical evaluation of a novel antibody-drug conjugate targeting DR5 for lymphoblastic leukemia therapy
Zhang, Shuyong
Zhou, Dongdong
Zheng, Chao
Xiong, Peng
Zhu, Wan
Zheng, Dexian
MOLECULAR THERAPY-ONCOLYTICS, 2021, 21 : 329 - 339
[47] Preclinical Studies of OBI-999: A Novel Globo H-Targeting Antibody-Drug Conjugate
Yang, Ming-Chen
Shia, Chi-Sheng
Li, Wan-Fen
Wang, Chun-Chung
Chen, I-Ju
Huang, Teng-Yi
Chen, Yu-Jung
Chang, Hui-Wen
Lu, Chi-Huan
Wu, Yueh-Chin
Wang, Nan-Hsuan
Lai, Jiann-Shiun
Yu, Cheng-Der
Lai, Ming-Tain
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (06) : 1121 - 1132
[48] Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma
Capone, Emily
Lamolinara, Alessia
Pastorino, Fabio
Gentile, Roberta
Ponziani, Sara
Di Vittorio, Giulia
D'Agostino, Daniela
Bibbo, Sandra
Rossi, Cosmo
Piccolo, Enza
Iacobelli, Valentina
Lattanzio, Rossano
Panella, Valeria
Sallese, Michele
De Laurenzi, Vincenzo
Giansanti, Francesco
Sala, Arturo
Iezzi, Manuela
Ponzoni, Mirco
Ippoliti, Rodolfo
Iacobelli, Stefano
Sala, Gianluca
CANCERS, 2020, 12 (10) : 1 - 18
[49] Antibody-drug conjugate for advanced melanoma?
Sharma, Sharan Prakash
LANCET ONCOLOGY, 2014, 15 (12): : E534 - E534
[50] Sacituzumab govitecan: an antibody-drug conjugate
Sahota, Sheena
Vahdat, Linda T.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (08) : 1027 - 1031

← 1 2 3 4 5 →